ANI eyes more deals to follow WellSpring

ANI Pharmaceuticals is looking for further deals to accompany the US firm’s organic growth, according to president and chief executive Arthur Przybyl. In August, ANI acquired for US$18 million Canada-based WellSpring Pharma Services, in a bid to expand its contract manufacturing and development business, and to increase the US firm’s capacity to re-commercialise its pipeline of ANDAs that require a technology transfer from its local Baudette facility in Minnesota (Generics bulletin, 31 August 2018, page 14).